Cystic Fibrosis Therapeutics in Major Developed Markets Cystic Fibrosis Therapeutics in Major Developed Ma | Page 2

2.1 Disease Introduction 7
2.2 Symptoms 8
2.3 Etiology 8
2.4 Pathophysiology 9
2.5 Diagnosis 9
2.6 Prognosis 10
2.7 Assessment of Disease Severity 10
2.8 Treatment 10
Access This Full Report @ http://www.radiantinsights.com/research/cystic-fibrosis-therapeutics-inmajor-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatmentand-market-growth
3 Marketed Products 12
3.1 Overview 12
3.2 Product Profiles 13
3.2.1 Pulmozyme (dornase alfa) - Genentech 13
3.2.2 Bronchitol (mannitol) - Pharmaxis 14
3.2.3 TOBI (tobramycin) - Novartis 15
3.2.4 TOBI Podhaler (tobramycin) - Novartis 16
3.2.5 Bramitob/Bethkis (tobramycin) - Chiesi Farmaceutici 17
3.2.6 Colobreathe (colistimethate sodium) - Forest Laboratories 17
3.2.7 Cayston (aztreonam) - Gilead Sciences 18
3.2.8 Kalydeco (ivacaftor) - Vertex Pharmaceuticals 19
3.2.9 Pancreatic Enzyme Replacement Therapies 20
3.2.10 Other Successful Products 21
3.3 Heat Map of Marketed Products 21
3.4 Conclusion 23